A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region

被引:90
作者
Cassier, P. A. [1 ]
Ducimetiere, F. [2 ]
Lurkin, A. [2 ]
Ranchere-Vince, D. [3 ]
Scoazec, J-Y [4 ,5 ]
Bringuier, P-P [4 ,5 ]
Decouvelaere, A-V [3 ]
Meeus, P. [6 ]
Cellier, D. [7 ]
Blay, J-Y [1 ,5 ,8 ]
Ray-Coquard, I. [1 ,2 ]
机构
[1] Ctr Leon Berard, Dept Med, F-69373 Lyon, France
[2] Soc Ctr Leon Berard, Sante EA4129, Lyon, France
[3] Ctr Leon Berard, Dept Pathol, F-69373 Lyon, France
[4] Hosp Civils Lyon, Hop Edouard Herriot, Dept Pathol, Lyon, France
[5] Univ Lyon 1, F-69622 Villeurbanne, France
[6] Ctr Leon Berard, Dept Surg, F-69373 Lyon, France
[7] Merck Serono, Lyon, France
[8] Ctr Leon Berard, U590, INSERM, F-69373 Lyon, France
关键词
gastrointestinal stromal tumour (GIST); incidence; KIT; PDGFRA; kinase mutations; GASTROINTESTINAL STROMAL TUMORS; C-KIT; PDGFRA MUTATIONS; IMATINIB; DIAGNOSIS; PATHOLOGY; PROGNOSIS; RESECTION; MESYLATE;
D O I
10.1038/sj.bjc.6605743
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Preliminary data indicate that the molecular epidemiology of localised gastrointestinal stromal tumour (GIST) may be different from that of advanced GIST. We sought to investigate the molecular epidemiology of sarcomas, including GIST, in the Rhone-Alpes region in France. PATIENTS AND METHODS: A prospective and exhaustive study in the Rhone-Alpes Region in France to assess the precise incidence of primary sarcomas with systematic centralised pathological review and molecular analysis was conducted for 2 consecutive years. RESULTS: Among 760 patients with a confirmed diagnosis of sarcoma, 131 (17%) had a GIST. The majority of patients had gastric primaries (61%). Mutational analysis could be performed in 106 tumour samples (74%), and 71 (67%) had exon 11 mutations. PDGFRA mutations were found in 16% of cases, which is twice as high as previously reported for advanced GIST. CONCLUSION: Data indicate that PDGFRA mutations in localised GIST may be twice as high as what was previously reported in patients with advanced disease. This finding may have important consequences for patients offered adjuvant imatinib, although most of these tumours are in the low-risk group. British Journal of Cancer (2010) 103, 165-170. doi: 10.1038/sj.bjc.6605743 www.bjcancer.com Published online 29 June 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:165 / 170
页数:6
相关论文
共 25 条
  • [1] Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations
    Agaimy, Abbas
    Wuensch, Peter H.
    Hofstaedter, Ferdinand
    Blaszyk, Hagen
    Ruemmele, Petra
    Gaumann, Andreas
    Dietmaier, Wolfgang
    Hartmann, Arndt
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (01) : 113 - 120
  • [2] BLACKSTEIN ME, 2010, 2010 GASTR CANC S OR
  • [3] KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs):: a population-based study
    Braconi, C.
    Bracci, R.
    Bearzi, I.
    Bianchi, F.
    Costagliola, A.
    Catalani, R.
    Mandolesi, A.
    Ranaldi, R.
    Galizia, E.
    Cascinu, S.
    Rossi, G.
    Giustini, L.
    Latini, L.
    Valeri, N.
    Cellerino, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (04) : 706 - 710
  • [4] Braggio DA, 2008, J CLIN ONCOL, V26
  • [5] PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
    Corless, CL
    Schroeder, A
    Griffith, D
    Town, A
    McGreevey, L
    Harrell, P
    Shiraga, S
    Bainbridge, T
    Morich, J
    Heinrich, MC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5357 - 5364
  • [6] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Debiec-Rychter, Maria
    Sciot, Raf
    Le Cesne, Axel
    Schlemmer, Marcus
    Hohenberger, Peter
    van Oosterom, Allan T.
    Blay, Jean-Yves
    Leyvraz, Serge
    Stul, Michel
    Casali, Paolo G.
    Zalcberg, John
    Verweij, Jaap
    Van Glabbeke, Martine
    Hagemeijer, Anne
    Judson, Ian
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1093 - 1103
  • [7] Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    DeMatteo, Ronald P.
    Gold, Jason S.
    Saran, Lisa
    Goenen, Mithat
    Liau, Kui Hin
    Maki, Robert G.
    Singer, Samuel
    Besmer, Peter
    Brennan, Murray F.
    Antonescu, Cristina R.
    [J]. CANCER, 2008, 112 (03) : 608 - 615
  • [8] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    DeMatteo, Ronald P.
    Ballman, Karla V.
    Antonescu, Cristina R.
    Maki, Robert G.
    Pisters, Peter W. T.
    Demetri, George D.
    Blackstein, Martin E.
    Blanke, Charles D.
    von Mehren, Margaret
    Brennan, Murray F.
    Patel, Shreyaskumar
    McCarter, Martin D.
    Polikoff, Jonathan A.
    Tan, Benjamin R.
    Owzar, Kouros
    [J]. LANCET, 2009, 373 (9669) : 1097 - 1104
  • [9] DU S, 2008, J CLIN ONCOL, V26, P10562
  • [10] EMILE JF, 2009, J CLIN ONCOL, V27, P10535